Several other analysts have also recently weighed in on HIK. Jefferies Group decreased their price objective on shares of Hikma Pharmaceuticals Plc from GBX 2,990 ($39.03) to GBX 2,500 ($32.63) and set a buy rating on the stock in a research note on Monday, September 12th. Barclays PLC reaffirmed an overweight rating and set a GBX 2,800 ($36.55) price objective on shares of Hikma Pharmaceuticals Plc in a research note on Thursday, August 4th. Numis Securities Ltd reissued a hold rating and set a GBX 2,660 ($34.72) price target on shares of Hikma Pharmaceuticals Plc in a research note on Wednesday, August 24th. Stifel Nicolaus reissued a buy rating on shares of Hikma Pharmaceuticals Plc in a research note on Friday, June 24th. Finally, Morgan Stanley decreased their price target on shares of Hikma Pharmaceuticals Plc from GBX 2,700 ($35.24) to GBX 2,500 ($32.63) and set an equal weight rating on the stock in a research note on Friday, August 12th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company currently has an average rating of Buy and a consensus price target of GBX 2,520.90 ($32.91).
Hikma Pharmaceuticals Plc (LON:HIK) traded down 0.10% on Friday, hitting GBX 2094.00. The company’s stock had a trading volume of 183,477 shares. The company’s market capitalization is GBX 4.73 billion. The company has a 50 day moving average price of GBX 2,202.30 and a 200-day moving average price of GBX 2,232.60. Hikma Pharmaceuticals Plc has a 1-year low of GBX 1,575.00 and a 1-year high of GBX 2,703.00.
In other news, insider Al-Husry,Ali bought 140,000 shares of the business’s stock in a transaction on Wednesday, August 31st. The shares were bought at an average cost of GBX 2,150 ($28.06) per share, for a total transaction of £3,010,000 ($3,928,990.99). Also, insider Ali Al-Husry bought 50,000 shares of the business’s stock in a transaction on Friday, September 23rd. The stock was purchased at an average price of GBX 2,099 ($27.40) per share, for a total transaction of £1,049,500 ($1,369,925.60).
About Hikma Pharmaceuticals Plc
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company develops, manufactures and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa (MENA) region and Europe.
Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with MarketBeat.com's FREE daily email newsletter.